Table 2.
Endpoint | Pyrotinib plus capecitabine(n = 134) | Lapatinib plus capecitabine(n = 132) | HR(95% CI) | p value |
---|---|---|---|---|
Median OS | Not reached | 26.9 months | 0.69 (0.48-0.98) | .02 |
Median PFS | 5.6 months | 12.5 months | 0.48 (0.37-0.63) | <.0001 |
Endpoint | Pyrotinib plus capecitabine(n = 134) | Lapatinib plus capecitabine(n = 132) | HR(95% CI) | p value |
---|---|---|---|---|
Median OS | Not reached | 26.9 months | 0.69 (0.48-0.98) | .02 |
Median PFS | 5.6 months | 12.5 months | 0.48 (0.37-0.63) | <.0001 |